{"nctId":"NCT01675635","briefTitle":"OxyNorm Capsules in Post-Operative Pain Study","startDateStruct":{"date":"2011-07"},"conditions":["Postoperative Pain"],"count":240,"armGroups":[{"label":"OxyNorm Capsules","type":"EXPERIMENTAL","interventionNames":["Drug: OxyNorm Capsules"]},{"label":"Morphine tablet","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Morphine tablet"]}],"interventions":[{"name":"OxyNorm Capsules","otherNames":["OxyNorm"]},{"name":"Morphine tablet","otherNames":["Morphine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients of either sex aged 18 to 80 years inclusive.\n2. Patients who have given written informed consent to participate in the study.\n3. Able and willing to communicate with the investigator and his/her staff.\n4. Free of anesthesia as assessed through question and answer interaction with nurse at which time oral medication is indicated.\n5. Reporting \"moderate\" or \"severe\" pain (VAS ≥ 4) related to surgery and requesting analgesics for pain relief.\n\nExclusion Criteria:\n\n1. Patients have developed tolerance to or dependence on narcotic analgesics and/or alcohol.\n2. Patients with ASA ≥ 3 .\n3. Have any concomitant medical condition that would be adversely affected by analgesics or confound the quantification of analgesia, or could affect the absorption, metabolism or excretion of the study drugs in any clinically significant fashion.\n4. Have known hypersensitivity to any of the study medications or related agents.\n5. Have taken analgesic medications within three hours (wash-out) prior to dosing.\n6. Have developed complications from the surgical procedure that would confound the study.\n7. Have a history of severe iatrogenic adverse experiences.\n8. Mothers nursing their infant during the 24 hours following study drug administration, or pregnant women.\n9. Patient with Nothing Per Os (NPO) as stated in patient's chart or physician's order.\n10. Surgery in patients with epidural anesthesia\n11. Patients with Severe impairment of liver at preoperative stage (ALT, AST ≥ 1.5 times upper limit) and abnormal renal function.\n12. Patients with medical history of recovering from abnormal surgery anesthesia.\n13. Patients with medical history of hypertension (Systolic blood pressure ≥ 180Hg, Diastolic blood pressure 110Hg).\n14. Patients with shock.\n15. Patients with COPD.\n16. According to investigator to determine, patients are in addition the inclusion criteria and exclusion criteria for any other reason than not suitable in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose)","description":"To measure resting VAS at 6h(±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison\n\nVisual Analogue Scale\n\n0 10 20 30 40 50 60 70 80 90 100\n\n0 means no pain; 100 means pain as bad as you can image at resting stage","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.21","spread":"9.53"},{"groupId":"OG001","value":"45.48","spread":"7.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.21","spread":"15.66"},{"groupId":"OG001","value":"19.94","spread":"15.68"}]}]}]},{"type":"SECONDARY","title":"VAS in Both Resting and Coughing Stage at 0.5h, 2h and 24h After Administration of First Dose","description":"To measure the resting and coughing VAS as 0.5h (±5min), 2h (±10min) and 24h (±20min) after administration of first dose, assessing the intensity of pain and to conduct inter-group comparison","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.21","spread":"9.53"},{"groupId":"OG001","value":"45.48","spread":"7.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.21","spread":"9.53"},{"groupId":"OG001","value":"45.48","spread":"7.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.87","spread":"13.59"},{"groupId":"OG001","value":"29.80","spread":"12.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.58","spread":"14.40"},{"groupId":"OG001","value":"20.89","spread":"12.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.73","spread":"12.52"},{"groupId":"OG001","value":"9.75","spread":"11.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.16","spread":"12.15"},{"groupId":"OG001","value":"53.91","spread":"10.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.20","spread":"12.12"},{"groupId":"OG001","value":"53.91","spread":"10.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.21","spread":"16.56"},{"groupId":"OG001","value":"37.96","spread":"13.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.68","spread":"17.91"},{"groupId":"OG001","value":"29.30","spread":"13.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.11","spread":"13.51"},{"groupId":"OG001","value":"16.27","spread":"12.58"}]}]}]},{"type":"SECONDARY","title":"The Use of Rescue Analgesics During the 24-hour Observation Period","description":"To calculate the subject who used rescue analgesics during the 4 dose interval within the 24-hour observation period and to conduct inter-group comparison","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"VAS in Coughing Stage at 6h (6h±20min After Administration of First Dose)","description":"To measure coughing VAS at 6h (±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison\n\nVisual Analogue Scale\n\n0 10 20 30 40 50 60 70 80 90 100\n\n0 means no pain; 100 means pain as bed as you can image applicable for both resting and coughing stage","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.16","spread":"12.15"},{"groupId":"OG001","value":"53.91","spread":"10.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.81","spread":"17.58"},{"groupId":"OG001","value":"28.15","spread":"16.79"}]}]}]},{"type":"SECONDARY","title":"Sleeping Quality Assessment","description":"To assess Sleeping quality assessment during 24 hours after administration of first dose and to conduct inter-group comparison\n\nSleeping quality scale\n\n1. Very Good\n2. Good\n3. Fair\n4. Bad\n5. Very Bad","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Satisfaction With Pain Control","description":"To assess the Satisfaction with pain control during 24 hours after administration of first dose and to conduct inter-group comparison\n\n1. Very Satisfied\n2. Satisfied\n3. Fair\n4. Not Satisfied\n5. Not Satisfied at all","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"43","spread":null}]},{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"58","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Total Amount of Study Drugs Used During the 24 Hours","description":"To calculate the total amount of study drugs used during the 24 hours and to conduct inter-group comparison\n\nThe study drug administration is average 6 hours,so the maximal is use 4 times in 24 hours. The investigate to evaluate if the subject need to take the 2nd, 3rd and 4th dose after the mandatory the 1st dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.50","spread":"10.37"},{"groupId":"OG001","value":"39.82","spread":"21.79"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":117},"commonTop":["Nausea","Vomiting","Dizziness","abdominal distension","postoperative infection"]}}}